Rafidah Saleh1, Aashraya Karpe1, Martin S Zinkernagel1,2,3, Marion R Munk4,5. 1. Department of Ophthalmology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland. 2. Department of Clinical Research, University Hospital Bern, Bern, Switzerland. 3. Bern Photographic Reading Center, Department of Ophthalmology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland. 4. Department of Ophthalmology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland. marion_munk@hotmail.com. 5. Bern Photographic Reading Center, Department of Ophthalmology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland. marion_munk@hotmail.com.
Abstract
PURPOSE: The purpose was to evaluate the effects of long-term anti-VEGF treatment on the retinal nerve fiber layer (RNFL) and retinal ganglion cell layer (RGCL) thickness for patients with neovascular AMD and glaucoma. METHODS: Medical records of respective patients who had received more than 15 anti-VEGF injections were reviewed. Initial and latest SD-OCT macular scans were segmented and changes of the RNFL and RGCL thickness at the four outer ETDRS quadrants were evaluated. Secondary outcome measures included changes of visual field parameters seen in automated perimetry. RESULTS: Sixteen patients were included (mean age 78 ± 6 years). The mean total number of anti-VEGF injections was 39 ± 16. The mean treatment duration was 6.1 ± 2.1 years. The mean IOP decreased from 18 ± 5 mmHg at baseline to 15 ± 5 mmHg at the last visit (p = 0.026). The mean RNFL thickness volume of the outer ETDRS quadrants (0.98 ± 0.18 mm3 to 0.97 ± 0.18 mm3 p = 0.61) and its average thickness (37.9 ± 7.3 μm to 37.2 ± 7.4 μm, p = 0.6) did not significantly change. However, the average RGCL thickness decreased significantly from 0.86 ± 0.12 mm3 to 0.79 ± 0.11 mm3 (p = 0.01), and from 27.7 ± 4.2 to 25.9 ± 3.7 μm (p = 0.01). Number of injections correlated with the RGCL change (r2 = 0.36, p = 0.01). The mean sensitivity, mean defect and absolute scotomata did not significantly change with p-values of 0.28, 0.21 and 0.07, respectively. CONCLUSION: Patients under long term treatment with anti-VEGF and concurrent glaucoma show significant decrease in macular RGLC volume. However, this decrease is comparable to reported RGCL decrease in patients under anti-VEGF treatment without underlying glaucoma and suggests that glaucoma patients may not be at a higher risk for losing macular RNFL and RGCL, at least if adequate control of intraocular pressure is maintained.
PURPOSE: The purpose was to evaluate the effects of long-term anti-VEGF treatment on the retinal nerve fiber layer (RNFL) and retinal ganglion cell layer (RGCL) thickness for patients with neovascular AMD and glaucoma. METHODS: Medical records of respective patients who had received more than 15 anti-VEGF injections were reviewed. Initial and latest SD-OCT macular scans were segmented and changes of the RNFL and RGCL thickness at the four outer ETDRS quadrants were evaluated. Secondary outcome measures included changes of visual field parameters seen in automated perimetry. RESULTS: Sixteen patients were included (mean age 78 ± 6 years). The mean total number of anti-VEGF injections was 39 ± 16. The mean treatment duration was 6.1 ± 2.1 years. The mean IOP decreased from 18 ± 5 mmHg at baseline to 15 ± 5 mmHg at the last visit (p = 0.026). The mean RNFL thickness volume of the outer ETDRS quadrants (0.98 ± 0.18 mm3 to 0.97 ± 0.18 mm3 p = 0.61) and its average thickness (37.9 ± 7.3 μm to 37.2 ± 7.4 μm, p = 0.6) did not significantly change. However, the average RGCL thickness decreased significantly from 0.86 ± 0.12 mm3 to 0.79 ± 0.11 mm3 (p = 0.01), and from 27.7 ± 4.2 to 25.9 ± 3.7 μm (p = 0.01). Number of injections correlated with the RGCL change (r2 = 0.36, p = 0.01). The mean sensitivity, mean defect and absolute scotomata did not significantly change with p-values of 0.28, 0.21 and 0.07, respectively. CONCLUSION:Patients under long term treatment with anti-VEGF and concurrent glaucoma show significant decrease in macular RGLC volume. However, this decrease is comparable to reported RGCL decrease in patients under anti-VEGF treatment without underlying glaucoma and suggests that glaucomapatients may not be at a higher risk for losing macular RNFL and RGCL, at least if adequate control of intraocular pressure is maintained.
Authors: K Bailey Freund; Jean-François Korobelnik; Robert Devenyi; Carsten Framme; John Galic; Edward Herbert; Hans Hoerauf; Paolo Lanzetta; Stephan Michels; Paul Mitchell; Jordi Monés; Carl Regillo; Ramin Tadayoni; James Talks; Sebastian Wolf Journal: Retina Date: 2015-08 Impact factor: 4.256
Authors: Frank G Holz; Winfried Amoaku; Juan Donate; Robyn H Guymer; Ulrich Kellner; Reinier O Schlingemann; Andreas Weichselberger; Giovanni Staurenghi Journal: Ophthalmology Date: 2011-04 Impact factor: 12.079
Authors: Swarup S Swaminathan; Anne L Kunkler; Ann V Quan; Charles M Medert; Elizabeth A Vanner; William Feuer; Ta Chen Chang Journal: Am J Ophthalmol Date: 2020-12-24 Impact factor: 5.488
Authors: Marion R Munk; Thomas Kurmann; Pablo Márquez-Neila; Martin S Zinkernagel; Sebastian Wolf; Raphael Sznitman Journal: Sci Rep Date: 2021-04-21 Impact factor: 4.379
Authors: Marion R Munk; Gabor Mark Somfai; Marc D de Smet; Guy Donati; Marcel N Menke; Justus G Garweg; Lala Ceklic Journal: Int J Mol Sci Date: 2022-07-08 Impact factor: 6.208
Authors: Pedro Henrique Victorino; Camila Marra; Dumitru Andrei Iacobas; Sanda Iacobas; David C Spray; Rafael Linden; Daniel Adesse; Hilda Petrs-Silva Journal: Genes (Basel) Date: 2021-03-11 Impact factor: 4.096